This industry first feature provides near real-time infectious disease mapping and reporting. With the power of Virena wireless connectivity and, all instrument and user history can be easily, securely and remotely accessed from any desktop. SAN DIEGO-(BUSINESS WIRE)- QuidelOrtho Corporation (NASDAQ: QDEL) (QuidelOrtho) announced completion of the transaction combining Quidel Corporation (Quidel) and Ortho Clinical Diagnostics Holdings plc (Ortho), creating QuidelOrtho, a leading in vitro diagnostics company. From the small physician office laboratory to larger hospital labs or emergency departments, Sofia's high performance, objectivity, quality control, fail-safe measures, LIS capabilities and expanding test menu make Sofia the perfect solution for those looking to improve their rapid testing algorithm. Sofia rapid test kits are easy to use, which means Sofia can be adapted to the needs of any healthcare setting. Sofia 2 has the power to deliver highly accurate, objective and automated Influenza A+B and RSV results fast. With Sofia 2’s proprietary Advance Result Technology (ART), Sofia 2 can produce and store results in as few as 3 minutes, giving you, your providers and your patients an accurate result, faster than ever before. Each of Quidel and Ortho commenced mailing copies of the definitive joint proxy statement/prospectus to stockholders of Quidel and Ortho, respectively, on or about April 11, 2022. Proven lateral-flow technology and proprietary advanced fluorescence chemistry and assay development techniques are all integrated into two small bench top analyzers that can be used near patient and in laboratory settings. JP Morgan Securities is acting as exclusive financial advisor to Ortho, while Latham & Watkins as legal advisor.Sofia, the next generation in diagnostic testing, takes rapid testing to a whole new level. Perella Weinberg Partners and Citi are serving as financial advisors to Quidel, while Gibson, Dunn & Crutcher as legal advisor. Subject to approval by both companies’ shareholders and customary closing conditions and regulatory approvals, the deal is expected to be completed in the first half of 2022. Quidel president and CEO Douglas Bryant said: “The combination with Ortho will help solidify Quidel as a leader in the diagnostics industry, bringing together innovative, complementary products, solutions, and services that enhance the health and well-being of patients across the globe.” If you have questions about this Privacy Notice, please contact us by e-mailing us at privacy&. It is expected to have a capability to meet patient testing requirements at all points of the care continuum, including reference labs, hospitals, physicians’ offices, urgent care centers and at-home / retail locations. The combined organisation will comprise advanced technologies and platforms, with expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings. Ortho chairman and CEO Chris Smith said: “Together, we will continue to advance life-changing diagnostic solutions to improve patient outcomes and deliver economic benefits to the healthcare system.” ![]() The company also offers Vitros menu of assays, Microtip partnership assays, Vitros automation solutions, HIV combo solutions and Vitros Covid-19 testing solutions. Its product portfolio consists of Vitros XT 7600 and Vitros 5600 integrated systems for chemistry and immunodiagnostic applications, and Vitros 3600 and Vitros ECiQ systems for immunoassay applications. SAN DIEGO, May 03, 2023-QuidelOrtho Corporation (Nasdaq: QDEL) (the Company or QuidelOrtho), a global provider of innovative in vitro diagnostic. The company’s technology and tools are used by hospitals, hospital networks, clinical laboratories and blood banks across the world. Ortho provides products and services to the global clinical laboratory and immunohaematology communities. Quidel will acquire Ortho’s common stock by paying $24.68 per share, in addition to paying $1.75bn in cash. Shares of Quidel and Ortho will cease trading after the market close on May 26, 2022, and following the closing, Ortho will no longer be listed on Nasdaq. Under the deal, Quidel will acquire Ortho using a combination of cash and newly issued shares in the combined company. (Credit: Belova59 from Pixabay)ĭiagnostic solutions manufacturer Quidel has agreed to acquire pure-play in vitro diagnostics (IVD) company Ortho Clinical Diagnostics for around $6bn. Ortho provides products and services to global clinical laboratory and immunohaematology communities. ![]() Savanna delivers fast, customizable, multiplex panels with superior molecular performance in an easy-to-use format. The combined organisation will comprise advanced technologies and platforms, including clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings Savanna is a multiplex real-time PCR testing platform with a simple sample-to-result operation that can run up to 12 unique analytes from a single patient sample in approximately 25 minutes.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |